## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG 2.37 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. The Technical Signals Behind (ZTS) That Institutions Follow**
- Source: Stock Traders Daily | 20251224T030903 | Neutral | Relevance: 100%
- This article provides a technical analysis of Zoetis Inc. Class A (NYSE: ZTS), highlighting stable neutral readings in shorter horizons and a mid-channel oscillation pattern. It presents an exceptional 34.2:1 risk-reward setup targeting a 10.0% gain. The analysis includes AI-generated entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies.

**2. Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025**
- Source: FinancialContent | 20251224T173000 | Somewhat-Bullish | Relevance: 98%
- In 2025, while the broader healthcare sector faced challenges, Zoetis Inc. (NYSE: ZTS) and Viatris Inc. (NASDAQ: VTRS) emerged as leaders due to their specialized focus on animal health and specialty/complex generics, respectively. Both companies demonstrated strong performance, with Viatris achieving a "beat and raise" quarter and Zoetis navigating regulatory scrutiny by highlighting its innovative pipeline in pet care. Their success underscores a shift towards specialized portfolios that are more resilient to policy changes and broader market volatility.

**3. Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025**
- Source: FinancialContent | 20251224T173000 | Somewhat-Bullish | Relevance: 94%
- Zoetis (NYSE: ZTS) and Viatris (NASDAQ: VTRS) are emerging as healthcare sector leaders in 2025, driven by their specialized portfolios in animal health and specialty/complex generics, respectively. Despite broader market headwinds, these companies have leveraged strategic innovation and strong earnings performances to outpace traditional pharmaceutical giants, attracting investors seeking durable growth. Their success highlights a shift towards niche markets in healthcare, insulated from policy changes affecting large pharma.

**4. Yousif Capital Management LLC Boosts Stock Holdings in Elanco Animal Health Incorporated $ELAN**
- Source: MarketBeat | 20251227T140906 | Neutral | Relevance: 62%
- Yousif Capital Management LLC significantly increased its stake in Elanco Animal Health Incorporated by 1,333.7% in Q3 2025, now holding 168,133 shares valued at $3.39 million. This comes as Elanco exceeded Q3 earnings expectations and provided strong FY2025 guidance. Insider buying and institutional ownership of nearly 97.48% also highlight confidence in the company.

**5. Albert White Bought 4.4% More Shares In Cooper Companies**
- Source: Simply Wall Street | 20251224T110104 | Neutral | Relevance: 59%
- Albert White, President of The Cooper Companies, Inc. (NASDAQ:COO), recently purchased US$808k worth of shares at an average price of US$80.80, increasing his holding by 4.4%. This significant insider buying suggests strong conviction in the company's future, as the transaction occurred at a price close to the current market value of US$82.88. Overall insider ownership in Cooper Companies stands at 0.6%, or US$95 million, indicating alignment between management and shareholder interests.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 14.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.37 elevated, pricing in significant growth expectations. Forward P/E 18.6x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $55.9B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.37 |
| Forward P/E | 18.6 |
| Current P/E | 19.9 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 1.2% (minimal 5-day change). Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Below SMA200 (0.85x), long-term trend not supportive. MACD histogram positive (1.15), confirming momentum. RSI neutral at 57. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.22% (CS: 90) | Neutral |
| RSI_14 | 56.8 | Neutral |
| MACD Histogram | 1.15 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 0.853x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $126.22
- **Stop Loss:** $120.36 (4.6% risk)
- **Target:** $132.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 225
- **Position Value:** $28,399.50
- **Portfolio %:** 28.40%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*